Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct 17:3:15.
doi: 10.1186/1741-7015-3-15.

Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

Clive Elliott Adams  1 , John Rathbone, Ben Thornley, Mike Clarke, Jo Borrill, Kristian Wahlbeck, A George Awad
Affiliations

Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

Clive Elliott Adams et al. BMC Med. .

Abstract

Background: Chlorpromazine (CPZ) remains one of the most common drugs used for people with schizophrenia worldwide, and a benchmark against which other treatments can be evaluated. Quantitative reviews are rare; this one evaluates the effects of chlorpromazine in the treatment of schizophrenia in comparison with placebo.

Methods: We sought all relevant randomised controlled trials (RCT) comparing chlorpromazine to placebo by electronic and reference searching, and by contacting trial authors and the pharmaceutical industry. Data were extracted from selected trials and, where possible, synthesised and random effects relative risk (RR), the number needed to treat (NNT) and their 95% confidence intervals (CI) calculated.

Results: Fifty RCTs from 1955-2000 were included with 5276 people randomised to CPZ or placebo. They constitute 2008 person-years spent in trials. Meta-analysis of these trials showed that chlorpromazine promotes a global improvement (n = 1121, 13 RCTs, RR 0.76 CI 0.7 to 0.9, NNT 7 CI 5 to 10), although a considerable placebo response is also seen. People allocated to chlorpromazine tended not to leave trials early in both the short (n = 945, 16 RCTs, RR 0.74 CI 0.5 to 1.1) and medium term (n = 1861, 25 RCTs, RR 0.79 CI 0.6 to 1.1). There were, however, many adverse effects. Chlorpromazine is sedating (n = 1242, 18 RCTs, RR 2.3 CI 1.7 to 3.1, NNH 6 CI 5 to 8), increases a person's chances of experiencing acute movement disorders, Parkinsonism and causes low blood pressure with dizziness and dry mouth.

Conclusion: It is understandable why the World Health Organization (WHO) have endorsed and included chlorpromazine in their list of essential drugs for use in schizophrenia. Low- and middle-income countries may have more complete evidence upon which to base their practice compared with richer nations using recent innovations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chlorpromazine versus placebo – global outcomes.
See this image and copyright information in PMC

References

    1. WHO Essential Medicines 13th edition. WHO Model List 2003 http://www.who.int/hac/techguidance/pht/essentialmed/en
    1. WHO Global Health Statistics Online, 1998 http://w3.whosea.org/en/section1174/section1199/section1567_6744.htm
    1. Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976–1985. Arch Gen Psychiatry. 1989;46:929–932. - PubMed
    1. Burgess S. Emergency drug treatment of disturbed psychotic patients. Auditorium. 1997;6:28–30.
    1. Norquist G, Hyman SE. Advances in understanding and treating mental illness: implications for policy. Health Aff. 1999;18:32–47. doi: 10.1377/hlthaff.18.5.32. - DOI - PubMed

Publication types